Jupiter Topco LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,546,841 shares of the biopharm

Quantbot Technologies LP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,342 shares of the biopharmaceutical company

Man Group plc acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,235,196 shares of the biopharmaceutical company

Ancora Advisors LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 121,465 shares of the biopharmaceutical company

Castleark Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 527,542 shares of the biop

Canada Pension Plan Investment Board acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,455,920 shares of the biopharmaceutical company

Roberts Glore & Co. Inc. IL bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 9,885 shares of the biopharmaceutical company

The Manufacturers Life Insurance Company purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,093,987 shares of the biopharmaceutical company

Ieq Capital LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 33,739 shares of the biopharmaceutica

Legal & General Group Plc bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,421,131 shares of the biopharmaceutical company

L2 Asset Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 64,505 shares of the biopharmaceutical company

Manning & Napier Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 102,792 shares of the biopharmaceutical company